We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+27.77%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$1.42B
AUM Growth
+$256M
(+22%)
Cap. Flow
+$65.4M
Cap. Flow
% of AUM
4.61%
Top 10 Holdings %
Top 10 Hldgs %
29.29%
Holding
112
New
24
Increased
30
Reduced
36
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$48.1M |
| 2 |
Replimune Group
REPL
|
+$27.8M |
| 3 |
Maravai LifeSciences
MRVI
|
+$27.3M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$25.6M |
| 5 |
Certara
CERT
|
+$22.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$51M |
| 2 |
HMSY
HMS Holdings Corp.
HMSY
|
+$18.7M |
| 3 |
Zentalis Pharmaceuticals
ZNTL
|
+$18.2M |
| 4 |
Aprea Therapeutics
APRE
|
+$17.9M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
+$16.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.8% |
| 2 | Industrials | 1.99% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Idexx Laboratories
IDXX
$44.1B
| $23.7M | 1.67% |
47,399
+6,200
| +15% | +$2.77M |
|
27
Arcus Biosciences
RCUS
$3.55B
| $22.4M | 1.58% |
861,160
-61,640
| -7% | -$1.49M |
|
|
28
Certara
CERT
$1.26B
| $20.4M | 1.44% |
+605,900
| New | +$22.2M |
|
29
Rocket Pharmaceuticals
RCKT
$340M
| $20.1M | 1.42% |
+367,385
| New | +$13.4M |
|
30
Zimmer Biomet
ZBH
$18.2B
| $18.6M | 1.31% |
+124,630
| New | +$17.6M |
|
31
American Well
AMWL
$180M
| $18.3M | 1.29% |
36,206
+5,948
| +20% | +$3.44M |
|
|
PRAH
32
DELISTED
PRA Health Sciences, Inc.
PRAH
| $17.2M | 1.21% |
136,770
+4,150
| +3% | +$464K |
|
|
MRTX
33
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $16.2M | 1.14% |
+73,638
| New | +$15.9M |
|
34
DexCom
DXCM
$31.5B
| $15.7M | 1.11% |
169,852
-23,800
| -12% | -$2.13M |
|
35
Revolution Medicines
RVMD
$39.9B
| $15.4M | 1.09% |
389,006
-244,084
| -39% | -$9.65M |
|
36
Centene
CNC
$30.7B
| $15.4M | 1.09% |
256,515
-133,575
| -34% | -$8.49M |
|
|
BPMC
37
DELISTED
Blueprint Medicines
BPMC
| $15.3M | 1.08% |
136,500
-158,233
| -54% | -$16.7M |
|
|
OSH
38
DELISTED
Oak Street Health, Inc.
OSH
| $15.3M | 1.08% |
+250,000
| New | +$13.1M |
|
39
Sarepta Therapeutics
SRPT
$1.57B
| $14.8M | 1.04% |
86,624
-5,650
| -6% | -$837K |
|
40
ResMed
RMD
$30.6B
| $14.1M | 0.99% |
66,305
-6,000
| -8% | -$1.2M |
|
41
Alnylam Pharmaceuticals
ALNY
$27.5B
| $14.1M | 0.99% |
+108,346
| New | +$14.5M |
|
|
ALXN
42
DELISTED
Alexion Pharmaceuticals
ALXN
| $13.7M | 0.97% |
87,976
+36,700
| +72% | +$4.72M |
|
43
Moderna
MRNA
$21.8B
| $13.2M | 0.93% |
126,306
-9,650
| -7% | -$976K |
|
|
FRLN
44
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| $12M | 0.85% |
43,833
-12,357
| -22% | -$3.11M |
|
45
Johnson & Johnson
JNJ
$618B
| $11.7M | 0.83% |
74,500
| – | – |
|
|
HOLX
46
DELISTED
Hologic
HOLX
| $11.5M | 0.81% |
158,300
+5,700
| +4% | +$402K |
|
47
Insulet
PODD
$11.5B
| $10.9M | 0.77% |
42,654
-2,000
| -4% | -$496K |
|
|
SGTX
48
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
| $10.8M | 0.76% |
+17,308
| New | +$7.85M |
|
49
TG Therapeutics
TGTX
$7.96B
| $10.7M | 0.76% |
+206,549
| New | +$6.98M |
|
50
AbbVie
ABBV
$443B
| $10.2M | 0.72% |
95,250
+9,000
| +10% | +$865K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q4 2020 Portfolio in Review
As of Q4 2020, Sectoral Asset Management held 112 positions worth $1.42B, up 22% from $1.16B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Sectoral Asset Management deployed $65.4M of net new capital in Q4 2020, opening 24 new positions and adding to 30 existing holdings. Its largest new stake was Atea Pharmaceuticals: 1,492,090 shares worth $62.3M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Aprea Therapeutics, an estimated $17.9M trimmed.
- Sectoral Asset Management's largest Q4 2020 buy was Atea Pharmaceuticals: 1,492,090 shares worth $62.3M.
- Sectoral Asset Management added most to Tandem Diabetes Care in Q4 2020, an estimated $25.6M increase.
- Sectoral Asset Management's biggest Q4 2020 reduction was Aprea Therapeutics, cutting an estimated $17.9M.
- Sectoral Asset Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $51M.
- Sectoral Asset Management's ten largest holdings make up 29% of its $1.42B portfolio in Q4 2020.
- Sectoral Asset Management opened 24 new positions and closed 15 in Q4 2020.
- Sectoral Asset Management's portfolio value rose 22% quarter-over-quarter to $1.42B.
Based on Sectoral Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.